Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease

被引：29

作者：

Hindryckx, Pieter ^{[1
]}

Novak, Gregor ^{[2
]}

Bonovas, Stefanos ^{[3
]}

Peyrin-Biroulet, Laurent ^{[4
]}

Danese, Silvio ^{[3
,5
]}

机构：

[1] Univ Ghent, Dept Gastroenterol, Ghent, Belgium

[2] Univ Ljubljana, Dept Gastroenterol, Med Ctr, Ljubljana, Slovenia

[3] Humanitas Clin & Res Ctr, IBD Ctr, Dept Gastroenterol, Milan, Italy

[4] Lorraine Univ, Univ Hosp Nancy, Inserm, U954, Vandoeuvre Les Nancy, France

[5] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 04期

关键词：

NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EVENT TRIAL TARGET; CARDIOVASCULAR SAFETY; CENTRAL SENSITIZATION; CHRONIC PAIN; CYCLOOXYGENASE ISOFORMS; OSTEOARTHRITIS PAIN; ARTHRITIS RESEARCH; KNEE REPLACEMENT; COX-2; INHIBITION;

D O I：

10.1002/cpt.791

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).

引用

页码：633 / 641

页数：9

共 50 条

[1] Biologic Therapy Is Not Associated With Increased Risk of Cancer or Infection in Elderly Patients With Inflammatory Bowel Disease
Chan, Jennifer
Roy, Abhik
Wade, Elijah
Tucker, Lue-Yen
Velayos, Fernando
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S949 - S949
[2] Biologic therapy and the risk of herpes zoster among patients with inflammatory bowel disease
Santella, Christina
Bitton, Alain
Filliter, Christopher
Vutcovici, Maria
Bessissow, Talat
Lakatos, Peter
Brassard, Paul
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 607 - 607
[3] Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease
Roig, Clara Amiama
Ferrer, Cristina Suarez
Garcia, Jose Luis Rueda
Cordon, Joaquin Poza
Sanchez-Azofra, Maria
Arranz, Eduardo Martin
Diaz, Irene Gonzalez
Costa, Carmen Amor
Martin-Arranz, Maria Dolores
GASTROENTEROLOGIA Y HEPATOLOGIA, 2023, 46 (02): : 109 - 115
[4] ASSOCIATION OF BIOLOGIC THERAPY OVERLAP WITH THE RISK OF INFECTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Kruger, Annie J.
Dormont, Flavio
Capit, Nicolas
Schilsky, Samantha
Roberts, Andrew
Lin, Yong
Badalamenti, Salvatore
Wiekowski, Maria
Bewtra, Meenakshi
Colombel, Jean Frederic
GASTROENTEROLOGY, 2024, 166 (05) : S1132 - S1133
[5] Biologic Therapy in Inflammatory Bowel Disease
Theede, Klaus
Dahlerup, Jens Frederik
Fallingborg, Jan
Hvas, Christian Lodberg
Kjeldsen, Jens
Munck, Lars Kristian
Nordgaard-Lassen, Inge
DANISH MEDICAL JOURNAL, 2013, 60 (06):
[6] Biologic therapy of inflammatory bowel disease
Sandborn, WJ
Targan, SR
GASTROENTEROLOGY, 2002, 122 (06) : 1592 - 1608
[7] Biologic therapy for inflammatory bowel disease
Ardizzone, S
Porro, GB
DRUGS, 2005, 65 (16) : 2253 - 2286
[8] Biologic Therapy for Inflammatory Bowel Disease
Sandro Ardizzone
Gabriele Bianchi Porro
Drugs, 2005, 65 : 2253 - 2286
[9] Biologic therapy for inflammatory bowel disease
Sands, BE
INFLAMMATORY BOWEL DISEASES, 1997, 3 (02) : 95 - 113
[10] Biologic therapy of inflammatory bowel disease
Baumgart, DC
Wiedenmann, B
Dignass, AU
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2003, 41 (10): : 1017 - 1032

← 1 2 3 4 5 →